BARDA calls on Novartis, GSK, Emergent to pitch in with Ebola drug
The U.S. government invested $440 million in three vaccine plants in the U.S. in 2012 with the proviso that if something like a pandemic occurred, it could call on them to produce drugs that it required. With Ebola spreading, those calls have now been made.
The race is on to test an experimental Ebola vaccine as West Africa grapples with an out-of-control outbreak and the U.S. scrambles to rectify breaches in protocol after a patient with the virus died at a Dallas hospital and a healthcare worker tested positive for the infection.
Mapp, HHS scrambling to find ways to supercharge production of Ebola drug
With Ebola rampaging through West Africa and now having reached the U.S., U.S. officials and the maker of an experimental Ebola drug manufactured from cells grown in tobacco leaves, ZMapp, want to expand the drug's current production while also seeing if traditional mammalian-cell methods might be used to quickly scale up production of the drug.
As the Ebola outbreak continues to ravage Liberia, Guinea and Sierra Leone, GlaxoSmithKline said Phase I trials of its experimental Ebola vaccine are expected to start in West Africa in the next few weeks, and Phase II trials are likely to begin in early 2015.
Officials search for ways to boost output of plant-made Ebola drugs
The Ebola crisis has reignited interest in green, plant-based production of drugs and vaccines, but also highlighted a problem with the approach: There isn't much capacity. Officials in the U.S. are trying to find ways around the capacity bottleneck.
Another vaccine hopeful is joining the fight against Ebola. Inovio Pharmaceuticals said this week that it will move its Ebola vaccine candidate into clinical trials in the first half of 2015.
As the death toll of West Africa's Ebola outbreak reaches 2,500, GlaxoSmithKline's experimental Ebola vaccine is being tested at the U.S. National Institutes of Health with no apparent ill effects so far, health officials report.
Ebola vaccine research is moving ahead at lightening speed thanks to combined public and private sector efforts, with GlaxoSmithKline unveiling fresh data showing that its experimental jab protected monkeys in a preclinical study.
BARDA helping Mapp Biopharmaceutical scale production of Ebola drug
The U.S. Biomedical Advanced Research and Development Authority is making money available to help drugmakers test and manufacture drugs that might help turn the tide of the Ebola outbreak in Africa.
Another Big Pharma player is joining the hustle toward an Ebola vaccine as the death toll surpasses 1,900 victims, eclipsing the total number of people who died from the disease in all previous outbreaks combined.